# Repeat-Dose Pharmacokinetics and Pharmacodynamics of Bortezomib in Patients With Relapsed Multiple Myeloma

> **NCT00080405** · PHASE1 · COMPLETED · sponsor: **Millennium Pharmaceuticals, Inc.** · enrollment: 40 (—)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Bortezomib

## Key facts

- **NCT ID:** NCT00080405
- **Lead sponsor:** Millennium Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-03
- **Primary completion:** 2005-06
- **Final completion:** —
- **Target enrollment:** 40 (—)
- **Last updated:** 2009-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00080405

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00080405, "Repeat-Dose Pharmacokinetics and Pharmacodynamics of Bortezomib in Patients With Relapsed Multiple Myeloma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00080405. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*